Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA (GPR64)
- Development stage
- Preclinical
- Lead developer
- Yonsei University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA (GPR64) refers to small interfering RNA molecules designed to silence the expression of the G-protein coupled receptor 64 (GPR64) gene. In the context of oncology research, specifically endometrial cancer, GPR64 has been identified as a potential tumor suppressor. Experimental depletion of GPR64 using siRNA in human endometrial adenocarcinoma cell lines (such as Ishikawa and HEC1A) has been shown to increase cell proliferation, colony formation, migration, and invasion. This suggests that GPR64 loss may contribute to cancer progression. The siRNA is primarily used as a research tool to investigate the biological function of GPR64 and its downstream signaling pathways, including the phosphorylation of AMPK and expression of Connexin 43.
- Other names
- GPR64 siRNAGPR-64 siRNAGPR 64 siRNAsiRNA targeting GPR64
02
Targets
ADGRG2
Beyond the preview
Go deeper on siRNA (GPR64).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA (GPR64).